TickerTalks
Browse all tickers →
TickerTalks›$INDP
ININDP

Indaptus Therapeutics, Inc.

$INDP·$156M·Biotechnology·Healthcare
$1.15+1.3%1Y-81.6%
Mentions · last 7 days
2026-08-26: 0 posts2026-08-27: 2 posts2026-08-28: 0 posts2026-08-29: 0 posts2026-08-30: 0 posts2026-08-31: 4 posts2026-09-01: 2 posts10
Price updated 2h ago·X counts updated 3h ago
ININDP
$INDPIndaptus Therapeutics, Inc.
$1.15+1.33%10 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $INDP, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-09-01

Falling on heavy selling — points lower unless it turns around.

Indaptus is a pre-clinical microcap at 3% of 52w range — the tape has essentially given up on the immunotherapy platform.

Indaptus Therapeutics Inc is a pre-clinical biotech developing immunotherapy platforms. Down 81% t12m with essentially no revenue, and the market has priced in significant dilution risk.

  • The business is pre-clinical: last four quarters printed $0 revenue with EPS from -$0.02 to -$3.74 — this is not an operating company, it's a research-stage catalyst bet with cash burn.
  • Analyst FY28 revenue estimate at $42M is aspirational, with FY26 EPS at -$6.34 and FY27 at -$4.42 reflecting continued heavy losses — that trajectory depends on clinical program advancement.
  • Position sits at only 3.0% of the 52-week range with volume 23% of normal — essentially abandoned by institutional flow, and the Aug 17 S-3 shelf registration is a real fresh dilution overhang.
  • The Abbott Cooper PLLC shareholder investigation (June 17) is legitimate legal risk, and the Aug 13 Q2 report showing $0 revenue confirms the operational base hasn't shifted.

The path forward requires a named clinical partnership with dollar-denominated payments, IND filing or Phase 1 initiation on a specific program, and any color on cash runway. Another quarter of thin operating progress plus a dilutive capital raise into the shelf registration confirms the breakdown; a named Big Pharma partnership with milestone payments restarts the case, but the setup here is negative-heavy.

What to watch: A named clinical partnership with dollar-denominated payments, IND filing or Phase 1 initiation on a specific program, and cash runway color. Another quarter of thin operating progress plus a dilutive capital raise into the shelf registration confirms the breakdown; a named Big Pharma partnership with milestone payments restarts the case.

On the calendar: 2026-11-17 — Q3 earnings

Read the AI verdict + X sentiment for $INDP

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Indaptus Therapeutics is a pre-clinical biotech developing a multi-pathway innate immune activator for cancer immunotherapy.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $INDP.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $INDP

Neutral — binary clinical-stage catalyst set is independent of the broader industry macro driver; pipeline readout timing is the company-specific event.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+50.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-0.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-130%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-9.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-303%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.02$-1.57+98.7%
Q1 2026May 15, 2026$-0.23$-1.87+87.7%
Q4 2025Mar 17, 2026$-3.10$-4.36+28.9%
Q3 2025Nov 12, 2025$-2.98$-4.17+28.5%
Next earningsTue, Nov 17·consensus EPS $-1.46

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.02$-1.9M
Q1 FY26$0———$-1.17$-7.0M
Q4 FY25$0———$-3.74$-3.2M
Q3 FY25$0———$-0.52$-3.1M

Forward consensus

4-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$6.34-$6.34 – -$6.340
FY27$0$0 – $0-$4.42-$4.42 – -$4.420
FY28$42.4M$42.4M – $42.4M$0.79$0.79 – $0.791
FY29$123.0M$123.0M – $123.0M$6.40$6.40 – $6.401

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.3%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-42.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-48.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 4.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.185-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMar 23David E. LazarDirector896.8K sh—

See when $INDP insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

S-3Shelf registrationAug 17S-3
AI summary

Indaptus Therapeutics (INDP) filed a new Form S-3 shelf registration statement on August 17, 2026, registering securities for delayed or continuous offering under Rule 415; Junyi Dai serves as CEO and is listed as the registrant contact. The total securities amount and security types are not visible in the excerpt. This is the second S-3 filing by Indaptus in 2026 (the first was filed June 26, 2026), providing ongoing capital raising flexibility amid significant ownership concentration from the March 2026 financing.

8-KShareholder voteAug 138-K — Item 2.02: Earnings release · Item 5.07: Shareholder vote
AI summary

Indaptus Therapeutics (INDP) issued a press release on August 13, 2026 announcing Q2 2026 (quarter ended June 30, 2026) financial results and business updates, furnished as Exhibit 99.1. Shareholders also voted on matters at the August 10, 2026 annual meeting (Item 5.07), with vote details not visible in the excerpt. Routine quarterly earnings and annual meeting reporting for a clinical-stage biotech; no quantitative details visible from the excerpt.

SC 13D/AActivist amendmentJun 26SC 13D/A
AI summary

Chenhao Xu (via Sino Lion Ventures Limited) filed Amendment No. 2 to Schedule 13D on Indaptus Therapeutics (INDP) as of June 24, 2026, reporting 38,895,000 shares (29.19% of 133,242,324 outstanding) acquired via conversion of Series AA and Series AAA Preferred Stock under a March 19, 2026 Securities Purchase Agreement, closed March 23, 2026. This is one of multiple related filers in the Indaptus ownership group. A 29.19% stake acquired through a preferred stock conversion represents near-controlling ownership in Indaptus; the coordinated group filing reflects a structured ownership group that collectively holds a majority of the company.

SC 13D/AActivist amendmentJun 26SC 13D/A
AI summary

Junyi Dai (CEO of Indaptus Therapeutics, INDP) filed Amendment No. 2 to Schedule 13D on June 24, 2026, disclosing direct ownership of 11,250,000 shares (8.44% of 133,242,324 outstanding), acquired via the same March 2026 preferred stock conversion. Dai is also part of the larger ownership group filing with Yun Yao and others. CEO insider ownership of 8.44% via a capital raise creates strong alignment but also concentration; Dai is both CEO and a large shareholder in the post-financing company.

SC 13D/AActivist amendmentJun 26SC 13D/A
AI summary

Ting Yang filed Amendment No. 2 to Schedule 13D on Indaptus Therapeutics (INDP) on June 24, 2026, disclosing direct ownership of 11,250,000 shares (8.44% of 133,242,324 outstanding), also acquired via the March 2026 preferred stock conversion; Yang is part of the ownership group with Yun Yao, Sino Lion Ventures, Chenhao Xu, and Junyi Dai. A third member of the concentrated ownership group at 8.44%; collectively the group of four holds approximately 77% of outstanding shares.

SC 13D/AActivist amendmentJun 26SC 13D/A
AI summary

Yun Yao (lead reporting person) filed Amendment No. 2 to Schedule 13D on Indaptus Therapeutics (INDP) on June 24, 2026, disclosing direct beneficial ownership of 41,991,000 shares (31.51% of 133,242,324 outstanding), acquired via the March 2026 preferred stock conversion. Yun Yao, as the largest single holder, effectively anchors a coordinated group (with Sino Lion Ventures, Chenhao Xu, Junyi Dai, and Ting Yang) that controls approximately 77% of Indaptus's outstanding shares.

S-3Shelf registrationJun 26S-3
AI summary

Indaptus Therapeutics (INDP) filed a Form S-3 shelf registration statement on June 26, 2026, registering securities for delayed or continuous offering under Rule 415; Junyi Dai is CEO. The total securities and dollar amount are not visible in the excerpt. This is the earlier of two S-3 filings in 2026 (the second was filed August 17, 2026), reflecting Indaptus's capital-raising posture following the concentrated March 2026 financing.

8-KMaterial agreementJun 248-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale
+ 21 other (5 8-Ks · 4 3s · 2 EFFECTs · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com·21d agoAbbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholdersglobenewswire.com·77d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$MRNA$ALT$CELU$NWBO$SLS$AMLX$ABCL
Voices on X · last 7 days

No standout posts about $INDP on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport